Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Prostate Cancer | Oncology Today with Dr Neil Love: An interview with Matthew R Smith, MD, PhD — Management of Prostate Cancer

53:21
 
Share
 

Manage episode 432164457 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring an interview with Dr Matthew R Smith, including the following topics:

  • Selection and sequencing of androgen-targeting therapies (0:00)
  • Evidence-based selection of treatment for metastatic hormone-sensitive prostate cancer (25:07)
  • New considerations with the use of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (27:44)
  • Role of novel radiopharmaceuticals for mCRPC (37:09)
  • Promising investigational approaches for prostate cancer (42:38)

CME information and select publications

  continue reading

1432 episodes

Artwork
iconShare
 
Manage episode 432164457 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring an interview with Dr Matthew R Smith, including the following topics:

  • Selection and sequencing of androgen-targeting therapies (0:00)
  • Evidence-based selection of treatment for metastatic hormone-sensitive prostate cancer (25:07)
  • New considerations with the use of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (27:44)
  • Role of novel radiopharmaceuticals for mCRPC (37:09)
  • Promising investigational approaches for prostate cancer (42:38)

CME information and select publications

  continue reading

1432 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide